Updated results from KEYNOTE-426 for metastatic kidney cancer
Published: 12 Jun 2020
Views: 127
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Dr Elizabeth Plimack talks to ecancer in an online interview for the ASCO virtual meeting 2020 about the KEYNOTE-426 study.
She outlines the trial design and explains the ongoing development of the study.
Dr Plimack discusses the updated results and maintained benefit of this combination.
Related Videos
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
Comment: JAVELIN-100 for metastatic urothelial cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
Perioperative novel systemic immunotherapy-based approaches in urinary cancers
Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA
9 Jun 2020
Immune checkpoint based approaches in AML and MDS
Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA
8 Apr 2020
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
7 Oct 2019
Latest developments in metastatic prostate cancer from ESMO 2019
Prof Nick James and Prof Nicholas Mottet
30 Sep 2019
